#United States #San Francisco #GRAIL #Galleri #Superpower

Superpower and GRAIL: A Groundbreaking Partnership in Cancer Detection

In a significant move towards revolutionizing health management, the proactive health platform, Superpower, has joined forces with GRAIL, Inc. This collaboration aims to bring the Galleri® multi-cancer early detection (MCED) test to Superpower members, reflecting a collective vision to evolve cancer screening methods in line with shifting disease patterns and prevention priorities.

A Changing Landscape in Cancer

Cancer remains one of the leading causes of death in the U.S., with statistics indicating that approximately 40% of Americans will receive a diagnosis at some point in their lives. What complicates matters further is the evolving nature of this disease; early-onset cancers, diagnosed in patients under 50, have surged nearly 80% since 1990 globally, hinting at an urgent need for improved detection measures. Traditional screening approaches have largely failed to adapt, often catching cancer only after it has progressed significantly.

Bridging the Early Detection Gap

Currently, cancer screening protocols generally address just a few cancer types, with many others slipping through the cracks. For instance, regular screenings like mammograms and colonoscopies predominantly cover only five major cancers, leaving almost 86% of other types undetected until symptoms manifest. This reality raises an inevitable question: why hasn't cancer detection kept pace with the realities of the disease?

Superpower's Executive Vice President, Prabhat Dhar, articulated this concern well: "The healthcare system often waits until issues are diagnosed to take action. This partnership with GRAIL is a pivotal change, enabling proactive screening for cancer signals, which can lead to early intervention when it's most effective."

The Galleri Test Explained

Through the new partnership, Superpower members will gain access to the innovative Galleri test, a clinically validated blood test capable of identifying signals from over 50 types of cancer. This groundbreaking test provides patients with crucial information regarding the origin of cancer signals, streamlining further diagnostic processes.

Data from GRAIL's PATHFINDER 2 study, which stands as the largest interventional study for multi-cancer early detection, showed that integrating Galleri into standard screenings improved detection rates by seven times. Impressively, many of the cancers identified were classified at stages I or II, where treatments typically yield better outcomes.

A Comprehensive Health Intelligence Approach

What sets Superpower apart is its holistic approach to health management. Unlike standalone screening services, Superpower integrates Galleri with a wide array of health metrics, offering members contextual interpretation alongside their biomarker panel of over 100 markers. Max Marchione, Superpower's CEO, emphasizes the importance of context in test results: "A test result without context can breed anxiety instead of actionable insights. Our platform connects cancer screening data with the full spectrum of an individual's health, enabling informed decision-making with care teams."

Implications for Employers

From a corporate perspective, the collaboration seeks to enhance population health management by providing clear visibility into potential cancer risks before they result in costly late-stage diagnoses. This proactive approach not only supports employees' health but also provides employers with insights into the health risks their workforce faces, allowing them to better tailor their healthcare offerings.

Josh Ofman, MD, President of GRAIL, expressed optimism about the partnership’s potential: "We are observing a transformative era in cancer screening. The integrated methodologies offered by Superpower in combination with GRAIL's multi-cancer detection capabilities represent the pathway forward in health management towards better cancer outcomes."

Accessing the Galleri Test

The Galleri test is available as an add-on through the Superpower platform, requiring a prescription primarily targeted towards adults at an elevated risk for cancer, notably those aged 50 and older. The test can be performed through Quest Diagnostics' extensive patient access network, offering convenient options either at home or in a clinical setting.

Conclusion

Superpower and GRAIL's partnership is set to alter the landscape of cancer detection and preventive healthcare. By providing sophisticated, early detection tools in a user-friendly format, they are committed to facilitating earlier interventions and saving lives through proactive health management.